



NAFLDsym[®] 2B

NAFLDsym[®] is Quantitative Systems Pharmacology (QSP) Software Capable of Exploring and Predicting Efficacy for Novel NASH Treatments

Key features of NAFLDsym v2B Beta within Julia include:

- Integration with a modern C++ based graphical user interface (GUI)
- Integration with the open-source Julia Scientific and Machine Learning (SciML) toolkit to solve simulations efficiently
- Results viewer that can open previously exported results files
- Pre-compiled Julia dependencies so users do not need to install a separate Julia environment
- An interactive console application for editing and appending to existing NAFLDsym QSP model equations

Sound Science

- NAFLDsym includes steatosis, lipotoxicity, inflammation, and fibrosis
- NAFLDsym is used to evaluate the efficacy potential of new drug candidates to treat non-alcoholic fatty liver disease (NAFLD) and non alcoholic steatohepatitis (NASH)
- NAFLDsym can be used to better understand NAFLD/NASH pathophysiology, progression, and treatment mechanisms
- DILIsym Services has leveraged its long standing expertise in liver physiology and metabolic diseases to develop NAFLDsym
- Successful simulation of more than 25 NAFLD/NASH compounds or targets within drug development to date



NAFLDsym predicts efficacy via the intersection between exposure, PD, and inter-patient pathophysiologic variability.

Application Driven

- Optimize clinical trial protocols by determining favorable dosing paradigms and outcome measurement frequency
- Evaluate targets and/or specific compounds utilizing key laboratory and/or clinical data describing DMPK and pharmacodynamic characteristics
- Evaluate combination therapy approaches
- Compare efficacy in different patient groups (i.e., stratification by NAS, by fibrosis score)
- Prioritize compounds and targets



simulations-plus.com/NAFLDsym +1-984-444-8305

Connect with us: